Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...

在今日的港股交易中，兆科眼科-B（06622）成为市场的异动股，其股价一度飙升超过8%，截至发稿时仍上涨5.83%，报1.27港元，成交额达到83.08万港元。这一涨幅主要得益于公司近日公布的临床试验结果，TAB014（公司的一款核心候选药物）在治疗 ...

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent ...

Twelve NHS bodies in the north east of England were offering these patients Avastin, a cheaper alternative to the licensed drug, Lucentis. David Hambleton, chief executive officer of NHS South ...

Narrator Verle was lucky. Out of 100 Emory Eye Center applicants, he was one of five chosen for a clinical trial of Lucentis, a new drug just approved by the FDA to treat the wet form of the disease.

Bs: Bevasiranib sodium; CABERNET: A study of Strontium 90 β Radiation With Lucentis to Treat Age-Related Macular Degeneration; CARBON: Combination of Bevasiranib and Lucentis Therapy in Wet AMD ...

The NORSE EIGHT non-inferiority study enrolled newly diagnosed wet AMD patients, who were randomly divided equally to receive either 1.25 mg ONS-5010 or 0.5 mg Lucentis (ranibizumab) intravitreal ...